Odyssey Therapeutics, Inc. (ODTX) vs Pacira BioSciences, Inc. (PCRX)
A side-by-side comparison of Odyssey Therapeutics, Inc. and Pacira BioSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ODTX
Odyssey Therapeutics, Inc.
$18.92HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
PCRX
Pacira BioSciences, Inc.
$24.74HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT
Total return — ODTX vs PCRX
growth of $100 · dividends reinvested · last 1yODTX +26.9% (+26.9%/yr)PCRX +6.0% (+6.0%/yr)ODTX compounded faster over this window
ODTX PCRX
ODTX vs PCRX: by the numbers
- •PCRX is the larger company ($973M vs $909M market cap).
- •PCRX is profitable (1.96% net margin) while ODTX runs a net loss (-4994.86%).
Metrics side by side
Valuation
| Metric | ODTX | PCRX |
|---|---|---|
| P/E ratio | N/A | 70.42 |
| P/S ratio | N/A | 1.30 |
| P/B ratio | 2.16 | 1.45 |
| EV / EBITDA | N/A | 11.38 |
| FCF yield | N/A | 18.45% |
Profitability
| Metric | ODTX | PCRX |
|---|---|---|
| Gross margin | 100.00% | 79.21% |
| Operating margin | -5415.19% | 2.47% |
| Net margin | -4994.86% | 1.96% |
| ROE | N/A | 2.18% |
| ROIC | -66.23% | 1.35% |
Growth (annualized)
| Metric | ODTX | PCRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 8.20% |
| EPS CAGR (5Y) | N/A | -45.77% |
| FCF CAGR (5Y) | N/A | 16.72% |
| Total return CAGR (5Y) | N/A | -12.27% |
Frequently asked
- Is ODTX or PCRX more profitable?
- PCRX runs the higher net margin — ODTX at -4994.86% versus PCRX at 1.96%.
Go deeper
Dig into the metrics
Pacira BioSciences P/E ratioOdyssey Therapeutics ROEPacira BioSciences ROEOdyssey Therapeutics operating marginPacira BioSciences operating marginOdyssey Therapeutics revenue growthPacira BioSciences revenue growthOdyssey Therapeutics free cash flowPacira BioSciences free cash flow
Odyssey Therapeutics & Pacira BioSciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.